<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625482</url>
  </required_header>
  <id_info>
    <org_study_id>2007-7041-121</org_study_id>
    <nct_id>NCT00625482</nct_id>
  </id_info>
  <brief_title>Sex-Differential Health Interventions In Low-Birth-Weight Infants</brief_title>
  <official_title>Sex-Differential Health Interventions In Low-Birth-Weight Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bandim Health Project</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>March of Dimes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bandim Health Project</source>
  <brief_summary>
    <textblock>
      Our group has consistently found that the major interventions to reduce morbidity and
      mortality in low-income countries have sex-differential effects. These interventions include
      BCG vaccine, oral polio vaccination (OPV), and vitamin A supplementation (VAS).

      Low-birth-weight (LBW) children constitute the largest high-risk group in low-income
      countries. According to current policy, they receive OPV at birth. Current evidence suggests
      that a policy of providing BCG with OPV for girls and VAS instead of OPV for boys at birth
      may improve survival in LBW neonates. This will be tested in a large randomized trial.

      We experienced an unexpected cluster of deaths among boys in the VAS arm, which could be due
      to chance, but we decided to stop randomizing boys to OPV or VAS. Very recent evidence has
      suggested that low-birth-weight boys may benefit from BCG at birth as well. Hence, we have
      obtained ethical permission to continue the trial with randomization of boys to OPV or OPV
      plus BCG.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall severe morbidity as measured by number of hospitalizations</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity due to rotavirus and malaria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCG scar formation and PPD delayed type hypersensitivity (DTH) response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cytokine profile</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <condition>Mortality</condition>
  <condition>Morbidity</condition>
  <condition>Growth</condition>
  <condition>Neonatal Mortality</condition>
  <arm_group>
    <arm_group_label>Boys 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OPV as usual</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boys 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPV plus BCG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Girls 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OPV as usual</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Girls 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPV plus BCG</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OPV</intervention_name>
    <arm_group_label>Boys 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OPV plus BCG</intervention_name>
    <arm_group_label>Boys 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OPV</intervention_name>
    <arm_group_label>Girls 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OPV plus BCG</intervention_name>
    <arm_group_label>Girls 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low-birth-weight infants (&lt;2500 g)

        Exclusion Criteria:

          -  Already received BCG/OPV

          -  Overtly sick or have malformations at the time of enrolment

          -  Clinical signs of vitamin A deficiency (very unlikely)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Bandim Health Project</name>
      <address>
        <city>Bissau</city>
        <country>Guinea-Bissau</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guinea-Bissau</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2008</study_first_submitted>
  <study_first_submitted_qc>February 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <last_update_submitted>October 22, 2013</last_update_submitted>
  <last_update_submitted_qc>October 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2013</last_update_posted>
  <keyword>BCG vaccine</keyword>
  <keyword>Oral polio vaccine</keyword>
  <keyword>Vitamin A supplementation</keyword>
  <keyword>Low-birth-weigth</keyword>
  <keyword>Sex-differential</keyword>
  <keyword>Prevention</keyword>
  <keyword>Immunological parameters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

